Mineralys Therapeutics (MLYS) Publishes Lorundrostat CKD Data, Is The Stock Still A Bargain?
Mineralys Therapeutics (MLYS) published Phase 2 data for lorundrostat in a top kidney journal, showing blood pressure and urinary protein reductions in chronic kidney disease patients. The stock is down 52.39% year-to-date and 37.01% over 90 days, despite the publication. Analysts forecast revenue of $463.2 million by November 2029 and a 3.3% profit margin in 3 years, with a fair value estimate of $45.22 per share, suggesting a 62% undervaluation.
How this was made
The 30-second read
Why it matters
The Phase 2 data provides the first substantive efficacy signal, potentially moving the stock toward its $45 fair value.
Market read
New clinical data could re‑price the stock and influence peer valuations in the CKD therapeutic space.
What to watch
The company still has no revenue and a heavy loss profile, which may limit upside despite data.
Background
Mineralys Therapeutics (MLYS) is a pre‑revenue biotech focused on lorundrostat for CKD and hypertension.
Ticker impact
Mineralys Therapeutics released Phase 2 Explore-CKD data for lorundrostat in a top kidney journal, providing new clinical evidence.
likely upward pressure as investors price in improved clinical outlook
First disclosure of trial results; data shows blood pressure and protein reduction, reducing clinical risk and supporting future FDA filing.
Market effects
May boost sentiment for the broader aldosterone synthase inhibitor space and CKD biotech sector.
Limited to US biotech investors; no broader regional effect.
Modest global relevance, primarily affecting niche biotech investors.
Counterpoint
Data, while positive, remain early-stage; risk of later trial failure could keep price depressed.
Key entities
- companyMineralys Therapeutics
Biotech developer of lorundrostat.
